Objectives To determine short-term outcome for children with acute liver failure (ALF) as it relates to cause, clinical status, and patient demographics and to determine prognostic factors.
A cute liver failure (ALF) is a dramatic clinical syndrome in which previously healthy children rapidly lose hepatic function and become critically ill within days. 1, 2 Over the last 25 years, single center experiences [3] [4] [5] [6] or general reviews 1,2,7 of pediatric ALF from Europe and North America identified a variety of infectious, metabolic, cardiovascular, and drug-related causes, as well as indeterminate cases. [4] [5] [6] These pediatric studies used the adult definition of ALF, which requires the presence of hepatic encephalopathy (HE) within 8 weeks of the development of clinical jaundice. Unfortunately, HE is difficult to assess in many infants and children and may not be essential to the diagnosis of ALF in children. 3, 8 The outcome for children with ALF remains poor for infants under 1 year of age, 3 patients with accidental acetaminophen overdose, 9 and Wilson's disease presenting with hepatic HE. 10 Spontaneous recovery (ie, survival without transplantation) remains between 15% to 20% for those with severe HE. 5, 6 Given the ongoing shortage of donor livers, 11 development of a reliable prognostic score will be useful in allocating organs to the most needy patients.
The Pediatric Acute Liver Failure (PALF) study group was formed in 1999 to develop a database that would facilitate an improved understanding of the pathogenesis, treatment, and outcome of ALF in children. These data will also serve to identify factors that will help to predict the likelihood of death or need for liver transplantation.
METHODS

Organization
The PALF study group began as an adjunct to the National Institutes of Health-sponsored, adult-focused ALF Study Group (William Lee, MD, Principal Investigator). The PALF study group now consists of 24 active pediatric sites, 21 within the United States, 1 in Canada, and 2 in the United Kingdom. Working groups of pediatric hepatologists established definitions for ALF and various diagnostic categories. Representatives from all participating centers approved final recommendations from the working groups. Patient enrollment began in December 1999.
Data Collection
Following informed consent from a parent or legal guardian, demographic, clinical and laboratory information were recorded daily for 7 days. In most patients, an additional aliquot of serum or plasma was collected on each of the 7 study days, frozen at Ϫ70°C, and then shipped to the Data Coordinating Center located at the University of Texas Southwestern Medical Center in Dallas, Texas. Diagnostic evaluation and medical management were consistent with the standard of care at each site. As in the adult study, our primary outcome measures determined at 3 weeks after entry into the study included death, death after transplantation, alive with native organ, and alive with transplanted organ. Completed data forms were forwarded under code to the Data Coordinating Center for review by the principal investigator for the pediatric study. If discrepancies were identified, the site was queried, and on resolution, data were then entered into the PALF database. The National Institutes of Health provided a Certificate of Confidentiality to the study and IRB approval was secured at each site before patient enrollment.
Subjects of the Study
Patients from birth through 18 years of age were eligible for enrollment if they met the following entry criteria for the PALF study: (1) children with no known evidence of chronic liver disease, (2) biochemical evidence of acute liver injury, and (3) hepatic-based coagulopathy defined as a prothrombin time (PT) Ն 15 seconds or international normalized ratio (INR) Ն 1.5 not corrected by vitamin K in the presence of clinical HE or a PT Ն20 seconds or INR Ն2.0 regardless of the presence or absence of clinical HE. A standard adult clinical coma grade scale was used for older children, and a coma grade scale was adapted for infants and children Ͻ 4 years old (Table I) . 
Diagnostic Categories
Diagnostic criteria for acute acetaminophen toxicity included a toxic serum acetaminophen level on the basis of the Rumack nomogram 13 or a history of an acute ingestion of 100 mg/kg within a 24-hour period. The diagnosis of autoim- 14 Non-acetaminophen drug-induced hepatitis was diagnosed if a temporal relationship between exposure to a suspected drug and the onset of ALF was established and other common causes were excluded. Hepatitis A, B, or C infection was confirmed serologically or by polymerase chain reaction. Evidence of other viral infections required a positive immunoglobulin M antibody, evidence of virus in liver tissue, or a positive polymerase chain reaction. Metabolic diseases were diagnosed by laboratory tests (eg, alpha-1-antitrypsin phenotype of ZZ), analysis of liver tissue (eg, mitochondrial enzyme defect), or analysis of cultured skin fibroblasts (eg, fatty acid oxidation defect). If the site investigator suspected an infection or metabolic disease but lacked supporting evidence or if a specific diagnosis could not be established, the final diagnosis was registered as indeterminate.
Statistical Methods
Diagnostic categories were defined as acetaminophen, indeterminate and all others in whom a specific diagnosis was determined. Age was dichotomized into patients younger than 3 years of age and those 3 years of age and older. Race was dichotomized into white versus non-white.
All associations between pairs of dichotomous or dichotomized variables (2-way tables) were conducted with 2 analyses. For those 2 analyses found significant, post hoc Tukey-type multiple comparison tests for proportions (TTMC) were performed. 15 The 2 independent samples proportions test with correction was used to compare proportions for two groups. Two different logistic regression models were used to predict death or transplantation in the 2 non-acetaminophen groups with data available at admission (coma grade, PT, and total bilirubin) and peak measures within the first 7 days of hospitalization or before transplantation (peak bilirubin, peak PT, maximum coma grade). These models also included sex (male vs female) and age (Ͻ3 vs Ն 3 years). SPSS V12.0 and SAS V9.1 were used in all analyses. The assumptions for all statistical tests were checked for violations. Statistical significance was set at P Ͻ .05.
RESULTS
Between December 1999 and December 2004, 348 children were enrolled; patient demographics are outlined in Table II . The median dose of acetaminophen ingested was 183 mg/kg (range 19.2 to 734.1). There was an association between cause and sex (P ϭ .0002), with the percentage of females significantly higher in the acetaminophen group compared with both non-acetaminophen groups (TTMC P Ͻ .05, 79% vs 46% or vs 60%, respectively). The association between the three etiologic categories and race (white vs non-white) was found to be significant (P ϭ .0275) with more whites in the acetaminophen versus the indeterminate group (TTMC P Ͻ .05, 67% vs 47%; respectively). Children under 3 years of age accounted for 36.5% (127/348) of patients ( Figure 1) . ALF caused by acetaminophen and those of indeterminate cause appear to occur more commonly during the cooler months, but this did not reach statistical significance (P ϭ .2240) (Figure 2 ).
HE at admission to the study and peak HE during the subsequent 7 days stratified by age and diagnosis is captured in Table III . HE was present more frequently in the combined non-acetaminophen groups than the acetaminophen group (56.6% [164/290] vs 39.6% [19/48] ; P ϭ .0425). In addition, the number of patients with development of HE during the 7-day study period was greater in those with non-acetaminophen ALF compared with the acetaminophen group (68.4% [203/297] vs 39.6% [19/48] ; P ϭ .0002). Patients in all diagnostic and age categories experienced worsening HE, although this occurred more commonly in older Table IV . Development of ascites, need for ventilator and blood pressure support, and requirement for red blood cell and plasma infusions were more likely to develop in patients within the 2 non-acetaminophen groups than in the acetaminophen group. In comparisons by age category, those in the younger age group were more likely to have development of ascites, require ventilator support, and infusions of red blood cells and fresh frozen plasma. Overall, a specific cause of ALF was not identified in 49% of patients and 54% of children less than 3 years of age. (Table V ; available at www.jpeds.com) acetaminophen toxicity accounted for only 14% of all patients, with 96% of these cases occurring in older patients. Specific viruses, drugs, toxins, and metabolic disorders are also listed in Table V . Interestingly, only 3 patients with acute hepatitis A infection, 1 patient with hepatitis C, and no patients with hepatitis B were identified in this cohort.
The short-term outcome for each diagnostic category is described in Table VI . When all cases are considered, the association between outcome and sex was significant (P ϭ .0428) with spontaneous recovery for females higher than for males (60% vs 46%, respectively), but this association disappears when the acetaminophen group is removed from the analysis. Survival and need for liver transplantation varied depending on the diagnosis. Spontaneous recovery was greatest in children with acetaminophen toxicity (45/48; 94%), worst for those with non-acetaminophen drug-induced liver injury (7/17; 41%) and with indeterminate cause (73/169; 43%). Patient outcomes on the basis of admission and peak HE are outlined in Table VII . Patients who never had HE were more likely to experience spontaneous recovery than those who did (78.9% vs 40.1%; P Ͻ .0001). In contrast, patients with development of stage III or IV HE had a spontaneous recovery rate of only 33% and 22%, respectively. Logistic regression analysis (Table VIII) to predict death or liver transplantation identified total bilirubin Ն 5 mg/dL, INR Ն 2.55, and HE to be risk factors if present on admission. The logistic regression model with peak values was similar to that for admission, with increasing predictive values (odds ratios) for all variables.
DISCUSSION
This report of the first 348 children in the PALF data set highlights a number of important observations: (1) HE is not an absolute requirement to establish the diagnosis of ALF in children; (2) a specific diagnosis was not made in almost half of all infants and children; (3) the causes of ALF in children differ from those seen in adults, 16 with children having more indeterminate cases and fewer acetaminophen and viral-induced cases; and (4) short-term outcome varied among diagnostic groups. HE is difficult to assess in children and, in fact, may never become clinically apparent in the setting of ALF. 3 However, coagulopathy is an independent risk factor for death or need for liver transplantation in ALF. 17 Therefore we chose to include children without HE in our study, but only when a significant uncorrectable coagulopathy was present. HE remains an important predictor of outcome 18 and, similar to other studies in the post-liver transplantation era, only 25% of our children with a peak HE of grade 3-4 had a spontaneous recovery. However, it is equally important to note that of 79 children with non-acetaminophen ALF who never had clinically detectable HE, death (8/79) or liver transplant (8/79) occurred in 20%. Our data support a definition of pediatric ALF that does not require HE.
An indeterminate cause of ALF was assigned to 54% of children Ͻ 3 years of age and 49% overall. Factors that may influence the intensity of the diagnostic evaluation in children with ALF include prioritization of the etiologic possibilities, blood volumes required for diagnostic studies, and the rapid evolution of disease to transplant or death. Thus all potential diagnostic studies were not performed on each patient. The indeterminate group may include patients who were "underevaluated" for known causes of ALF, as well as those with novel infectious, immune, autoimmune, metabolic, or genetic disorders. An infectious agent was identified in only 6% of patients in this series. Herpes simplex virus and Epstein Barr virus were the most common identifiable infections in children Ͻ3 years and Ն3 years, respectively. Hepatitis A and B are commonly associated with ALF in adults 19 ; however, we identified only 3 cases of hepatitis A, one case of hepatitis C, and no cases of hepatitis B. Nevertheless, these infections are common causes of ALF in children living in endemic areas where hepatitis A can represent up to 40% of ALF cases. 20 Respiratory viruses, enterovirus, or perhaps medications used for symptomatic treatment of these conditions might be implicated given the surge of cases in the winter months; however, these viruses were rarely identified.
AIH presenting as ALF accounted for 6% of patients, occurred in all age groups and should therefore be considered early in the diagnostic evaluation to enable timely initiation of corticosteroid treatment. 21 A metabolic cause for ALF was established in 18% of children Ͻ3 years of age. Unfortunately, diagnostic criteria for several conditions are not well established, and special attention to proper collection and transport of biological specimens to specialized research laboratories is needed. Wilson disease and defects or deficiencies in mitochondrial function and metabolism (ie, mitochondrial hepatopathy) were the most common metabolic conditions identified in our study.
Acute acetaminophen toxicity is the most common identifiable cause of ALF in children Ն3 years old (21%), but the frequency is even higher in adults (40%). 22 Instances involving prolonged or inappropriate dosing, so-called "therapeutic misadventures," 23 are not easily captured by this study. Acetaminophen-protein adducts are formed when the usual mechanisms of acetaminophen metabolism and excretion are exhausted, and the reactive acetaminophen metabolite binds to important intracellular proteins, resulting in cell death. Detection of these adducts in serum may serve as a biomarker of acetaminophen toxicity. 24 Non-acetaminophen drug-related ALF was recognized only in the older age group in our series. Drug-related hepatotoxicity is relatively common in children, particularly those taking neuroleptic medications, yet ALF is rare. 25, 26 The mechanism of injury leading to ALF is believed to be an idiosyncratic reaction in most cases; however, children with ALF related to valproic acid should be evaluated for an underlying mitochondrial disorder. 27 In addition, polymorphisms of genes associated with drug detoxification or cytokine expressions may enhance a patient's susceptibility to liver injury. 28, 29 Patient outcome was influenced by a number of factors including age, diagnosis, the degree of HE, and severity of the coagulopathy. The risk of death or liver transplantation was highest among children Ͻ3 years of age. Although the numbers are relatively small, patients with grade IV HE at enrollment experienced a higher rate of spontaneous recovery than those who progressed to grade IV during the course of the study (50% vs 20%). At the same time, 20% of children who never experienced clinical HE either died or received a liver transplant. Logistic regression analysis identified total bilirubin Ն 5 mg/dL, INR Ն 2.55, and HE to be risk factors to predict death or liver transplantation.
In summary, this multicenter, multinational database has confirmed that acetaminophen-induced ALF has an excellent outcome when HE is absent, 30 demonstrated that the causes of ALF in children are age-dependent and differ from those in adults, and identified AIH as an important cause of ALF in all ages of children. Unfortunately, most cases of ALF in children are indeterminate. Therefore improvement in diagnosis will require a focused search for treatable causes that prioritizes diagnostic conditions known to cause ALF. Newer techniques to identify children with an underlying metabolic disease, acetaminophen toxicity, and immune dysregulation will likely improve our ability to establish a diagnosis in these seriously ill children. 9 (7) 11 (5) 20 ( 
